Edition:
United States

Fibrocell Science Inc (FCSC.OQ)

FCSC.OQ on NASDAQ Stock Exchange Capital Market

0.61USD
20 Apr 2018
Change (% chg)

$-0.01 (-1.47%)
Prev Close
$0.62
Open
$0.61
Day's High
$0.63
Day's Low
$0.60
Volume
14,258
Avg. Vol
93,352
52-wk High
$4.59
52-wk Low
$0.51

Chart for

About

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either... (more)

Overall

Beta: 0.51
Market Cap(Mil.): $13.95
Shares Outstanding(Mil.): 22.43
Dividend: --
Yield (%): --

Financials

  FCSC.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -1.43 -- --
ROI: -102.85 -0.74 13.19
ROE: -244.29 -2.80 15.00

BRIEF-Fibrocell Announces Review Of Strategic Alternatives

* FIBROCELL SCIENCE INC - HAS ENGAGED CANACCORD GENUITY LLC AS ITS STRATEGIC FINANCIAL ADVISOR TO ASSIST WITH THIS REVIEW PROCESS

Apr 18 2018

BRIEF-Fibrocell Reports 2017 Financial Results And Recent Highlights

* FIBROCELL REPORTS 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS Source text for Eikon: Further company coverage:

Mar 19 2018

BRIEF-Fibrocell Announces FDA Allowance Of Investigational New Drug Application For FCX-013

* FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA

Mar 06 2018

BRIEF-Fibrocell Science Says‍ Expect To Initiate A Safety Clinical Trial In 2018 For Fcx-013 Development

* FIBROCELL SCIENCE SAYS‍ EXPECT TO INITIATE A SAFETY CLINICAL TRIAL IN 2018 FOR FCX-013 DEVELOPMENT - SEC FILING​ Source text for Eikon: Further company coverage:

Feb 05 2018

BRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin Disorder

* FIBROCELL SCIENCE SAYS SUBMITTED INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA​ Source text for Eikon: Further company coverage:

Feb 05 2018

BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007

* FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)

Jan 30 2018

BRIEF-Fibrocell Science Says Expects IND Filing Of FCX-013 In Q1 2018

* FIBROCELL SCIENCE INC SAYS EXPECTS IND FILING OF FCX-013 IN Q1 2018 AND INITIATE SAFETY CLINICAL TRIAL IN 2018 - SEC FILING Source text: (http://bit.ly/2EaJQ01) Further company coverage:

Dec 29 2017

BRIEF-Fibrocell Science Q3 loss per share $‍0.02​

* Fibrocell reports third quarter 2017 financial results and recent highlights

Nov 13 2017

BRIEF-Fibrocell Science files for common stock offering of up to $23 mln

* Fibrocell Science Inc files for common stock offering of up to $23 million - SEC filing‍​ Source text: (http://bit.ly/2AoC3tG) Further company coverage:

Nov 06 2017

Earnings vs. Estimates